Marco Meglio

The label expansion now allows patients who require non-brain MRI monitoring to receive treatment with the stimulation device.

Despite the introduction of second-generation ASMs, drug tolerability has been relatively unchanged over the last 30 years.

The drug’s Prescription Drug User Fee Act date is set for October 20, 2020.

Compared with intensive care units or normal wards, stroke units were associated with reduced mortality in patients with intracranial hemorrhage.

Patients with relapsing multiple sclerosis showed declining scores on tests of cognitive processing speeds from baseline to 3-month follow-up post-relapse.

The chief executive officer of Clene Nanomedicine discussed CNM-Au8, their novel investigational drug that will be used in the world’s first platform trial of potential ALS treatments.

Both the 10- and 20-mg doses were associated with clinically relevant reductions in convulsive seizures with a favorable safety and tolerability profile.

Similar effects were observed for each proxy SMPS component when compared with placebo.

When performed by itself, endovascular therapy had greater rates of intracranial hemorrhage compared to a combination of both endovascular therapy and intravenous thrombolysis.

The drug was previously approved for the treatment of acute repetitive seizures and granted 7 years of orphan drug exclusivity in January 2020.

Gaboxadol is the first treatment in 50 years associated with positive change in outcomes in Angelman syndrome.

Neurology News Network for the week ending February 29, 2020.

The president and founder of Cure Rare Disease discussed the company’s custom therapeutics for patients with rare diseases, including the use of CRISPR gene-editing technology to develop treatments for Duchenne muscular dystrophy.

Compared with patients who initially received interferon treatment, those given ocrelizumab had superior disability progression after a 6-year follow-up.

Patients with a disease duration of <16 years demonstrated a significantly greater reduction in risk for confirmed disability progression (CDP) at 3 and 6 months.

The orally administered tyrosine kinase inhibitor was shown to delay disability progression in patients with primary progressive multiple sclerosis.

Stroke patients experienced higher rates of thrombolysis as well as faster alarm to treatment times when mobile stroke units were present.

Retrotope had already received FDA approval to test RT001, a chemically modified polyunsaturated fatty acid agent, in expanded access trials of 3 patients with progressive supranuclear palsy.

Secondary endpoints and final results from the clinical study will be announced at the end of March 2020.

Patients 65 and under were more likely to develop seizures following a stroke than older patients.

Self-administration of the drug led to statistically significant motor status changes within 30 minutes of treatment.

The model may help clinicians enact preventative measures for those with migraine with aura at an early stage.

Patients with Parkinson disease with moderate to severe white matter hyperintensity (WMH) burden had a greater risk of developing levodopa-induced dyskinesia compared with those with minimal WMHs.

Good functional recovery at 3 months is achieved in approximately a quarter of patients with acute ischemic stroke with large-vessel occlusion due to calcified emboli.

The revision accounts for data from the NURTURE trial showing that patients with 3 copies of SMN2 greatly benefit from early treatment.

Patients with Huntington disease who received antihypertensive medication had slower disease progression less cognitive impairment compared with patients with untreated hypertension.

The DWI-based hierarchic algorithm predicted the risk of disability at 3 months for up to 100% of patients with a high predictive value.

The Nippon Shinyaku investigational DMD agent has a Prescription Drug User Fee Act date within the third quarter of 2020.

When compared with placebo, prophylactic pharmacologic treatments showed no significant long-term effects in pediatric patients with migraine.

Stress coping abilities may have a direct impact on the early accumulation of tau pathology.